Calypte!!! Was seht ihr als realistisches Kursziel
Seite 97 von 106 Neuester Beitrag: 06.10.03 17:08 | ||||
Eröffnet am: | 03.09.03 07:21 | von: Biomedi | Anzahl Beiträge: | 3.625 |
Neuester Beitrag: | 06.10.03 17:08 | von: standingovat. | Leser gesamt: | 84.549 |
Forum: | Hot-Stocks | Leser heute: | 55 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 94 | 95 | 96 | | 98 | 99 | 100 | ... 106 > |
Bis dann, ZN
THURSDAY, OCTOBER 02, 2003 12:55 PM
- PR Newswire
ALAMEDA, Calif., Oct 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (CYPT) , the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced today that Marr Technologies Limited had increased its ownership in Calypte Biomedical through the open-market purchase of approximately 5.2 million shares of the company's common stock. Marr had previously invested $12.5 million in the company's stock through a private placement of securities.
"We are confident in Calypte's HIV screening technology," said Marat Safin, President of Marr Technologies Limited. "We believe it will penetrate the global markets. Since the company is already well financed, we have acquired an additional 5.2 million shares in the company in the open market."
The recent purchases increase Marr's ownership position to approximately 38 million shares.
About Marr Technologies Limited
Marr Technologies Limited is a member of the Marr Group of companies (the "Group"). The Group is a private group controlled by the Safin family and administered from London. Marat Safin, a London School of Economics graduate, is the President of the Group. The Group has a large and diverse number of investments and projects globally, principally in Europe, the Far East, the Middle East and the CIS, with substantial investments in telecoms and technology projects. The Group has made significant progress in placing products and services of its group companies in the Chinese market and believes that its experience in China will greatly benefit the joint venture with Calypte.
Gruss Sam
ALAMEDA, Calif., Oct 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced today that Marr Technologies Limited had increased its ownership in Calypte Biomedical through the open-market purchase of approximately 5.2 million shares of the company's common stock. Marr had previously invested $12.5 million in the company's stock through a private placement of securities.
"We are confident in Calypte's HIV screening technology," said Marat Safin, President of Marr Technologies Limited. "We believe it will penetrate the global markets. Since the company is already well financed, we have acquired an additional 5.2 million shares in the company in the open market."
The recent purchases increase Marr's ownership position to approximately 38 million shares.
"We believe it will penetrate the global markets."
Gruß, sireuitz
Inzwischen haben wir sogar zwei Meldungen per Week! Es kommt Bewegung in den Laden!
Hinzu kommen noch die SEC Fillings, die den Titel ins Gespräch bringen! Jetzt haben wir doch, was wir wollten. Die $1-Marke wurde getestet und es ist klar, dass der urs nicht darunter fallen soll/wird!!!
2-Oct-2003 Marr Technologies Increases Investment in Calypte Biomedical Corporation
1-Oct-2003 Calypte Biomedical Corporation Plans New Initiative With The AIDS Action Council In Africa
24-Sep-2003 Calypte Biomedical to Test its Urine Based HIV-1 Test in Tanzania, Rwanda, Burundi and Botswana
9-Sep-2003 Calypte's HIV-1 Antibody Tests Approved For Distribution in the Republic of Uganda
2-Sep-2003 Calypte Receives $10 Million Investment
26-Aug-2003 Calypte and World Health Organization Reach Agreement to Accelerate Review Of HIV EIA and Western Blot Evaluations Phase 2 No Longer Required
12-Aug-2003 Calypte Biomedical Announces Resumption of Product Distribution in China